Toll Free: 1-888-928-9744

Nerve Injury - Pipeline Review, H1 2016

Published: Feb, 2016 | Pages: 73 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Nerve Injury - Pipeline Review, H1 2016

Summary
Global Markets Direct's, 'Nerve Injury - Pipeline Review, H1 2016', provides an overview of the Nerve Injury pipeline landscape. The report provides comprehensive information on the therapeutics under development for Nerve Injury, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Nerve Injury and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Nerve Injury - The report reviews pipeline therapeutics for Nerve Injury by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Nerve Injury therapeutics and enlists all their major and minor projects - The report assesses Nerve Injury therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Nerve Injury Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Nerve Injury - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Nerve Injury pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Nerve Injury Overview 8 Therapeutics Development 9 Pipeline Products for Nerve Injury - Overview 9 Pipeline Products for Nerve Injury - Comparative Analysis 10 Nerve Injury - Therapeutics under Development by Companies 11 Nerve Injury - Therapeutics under Investigation by Universities/Institutes 12 Nerve Injury - Pipeline Products Glance 13 Clinical Stage Products 13 Early Stage Products 14 Nerve Injury - Products under Development by Companies 15 Nerve Injury - Products under Investigation by Universities/Institutes 16 Nerve Injury - Companies Involved in Therapeutics Development 17 Acorda Therapeutics, Inc. 17 Biogen, Inc. 18 Caladrius Biosciences, Inc. 19 Calico LLC 20 F. Hoffmann-La Roche Ltd. 21 Human Stem Cells Institute 22 Kineta, Inc. 23 Kolon Life Science, Inc. 24 Medtronic plc 25 Neuralstem, Inc. 26 Neurotune AG 27 SanBio, Inc. 28 TissueGene, Inc. 29 Nerve Injury - Therapeutics Assessment 30 Assessment by Monotherapy Products 30 Assessment by Target 31 Assessment by Mechanism of Action 33 Assessment by Route of Administration 35 Assessment by Molecule Type 37 Drug Profiles 39 3K3A-APC - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 cimaglermin alfa - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 CLP-257 - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 KLS-Nst - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 MDT-15 - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 Neovasculgen - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 NSI-566 - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 NT-1654 - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 raxatrigine hydrochloride - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 SB-618 - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 Small Molecules to Activate NAMPT for Neurological Disorders - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 Stem Cell Therapy for Sciatic Nerve Regeneration - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 Synthetic Peptides to Inhibit PDE-4A4 for Pulmonary Fibrosis and Nerve Injury - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 TG-N - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 U-2902 - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 Nerve Injury - Recent Pipeline Updates 59 Nerve Injury - Dormant Projects 70 Nerve Injury - Discontinued Products 71 Appendix 72 Methodology 72 Coverage 72 Secondary Research 72 Primary Research 72 Expert Panel Validation 72 Contact Us 72 Disclaimer 73
List of Tables
Number of Products under Development for Nerve Injury, H1 2016 9 Number of Products under Development for Nerve Injury - Comparative Analysis, H1 2016 10 Number of Products under Development by Companies, H1 2016 11 Number of Products under Investigation by Universities/Institutes, H1 2016 12 Comparative Analysis by Clinical Stage Development, H1 2016 13 Comparative Analysis by Early Stage Development, H1 2016 14 Products under Development by Companies, H1 2016 15 Products under Investigation by Universities/Institutes, H1 2016 16 Nerve Injury - Pipeline by Acorda Therapeutics, Inc., H1 2016 17 Nerve Injury - Pipeline by Biogen, Inc., H1 2016 18 Nerve Injury - Pipeline by Caladrius Biosciences, Inc. , H1 2016 19 Nerve Injury - Pipeline by Calico LLC, H1 2016 20 Nerve Injury - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 21 Nerve Injury - Pipeline by Human Stem Cells Institute, H1 2016 22 Nerve Injury - Pipeline by Kineta, Inc., H1 2016 23 Nerve Injury - Pipeline by Kolon Life Science, Inc., H1 2016 24 Nerve Injury - Pipeline by Medtronic plc, H1 2016 25 Nerve Injury - Pipeline by Neuralstem, Inc., H1 2016 26 Nerve Injury - Pipeline by Neurotune AG, H1 2016 27 Nerve Injury - Pipeline by SanBio, Inc., H1 2016 28 Nerve Injury - Pipeline by TissueGene, Inc., H1 2016 29 Assessment by Monotherapy Products, H1 2016 30 Number of Products by Stage and Target, H1 2016 32 Number of Products by Stage and Mechanism of Action, H1 2016 34 Number of Products by Stage and Route of Administration, H1 2016 36 Number of Products by Stage and Molecule Type, H1 2016 38 Nerve Injury Therapeutics - Recent Pipeline Updates, H1 2016 59 Nerve Injury - Dormant Projects, H1 2016 70 Nerve Injury - Discontinued Products, H1 2016 71



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify